Monthly revenue YoY ≥ 20% (from filing deadline)
Active · now 27.05%Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).
Copy the prompt to get recent events, historical reactions, and a short research brief.
Tell your AI:
Help me set up FinLab and analyze 4585 達明. Please read: https://finlab.finance/en/setup?stock=4585
steady quality, premium valuation.
Above-average profitability.Operating margin is in the 47th market percentile. Latest quarterly ROE ≈ 1.0%.
Valuation is high.PE is in the 96th market percentile.
Foreign investors are net selling.Foreign 20-day net flow ≈ -1.6% of volume (net sell).
Strong revenue growth.Latest monthly revenue YoY ≈ 27.1%, above the 20% growth threshold.
Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.
Institutional rotation, concentration steady — bullish
Window from 2026-01-17 · Price -9% · branches to 2026-06-17· TDCC to 2026-06-12
Weak direction: big-holder share fell while retail share rose.
Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.
These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.
Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).
Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.
Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.
These are not occurring now; historical samples shown for comparison.
Adjusted close makes a new 252-day high; repeats within 20 days counted once.
Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.
達明機器人股份有限公司,股票簡稱達明,代號4585,為臺灣上市普通股。公司成立於2015年9月18日,最初由廣明光電轉投資設立,總部與公司地址位於桃園市龜山區華亞二路58-2號5樓,工廠位於同址7樓。董事長為何世池,總經理為陳尚昊,發言人為王偉霖。公開發行日期為2021年10月12日,興櫃登錄日期為2024年9月26日,上市日期為2025年9月26日。公開資訊與券商資料顯示,上市後資本額約新台幣10.46億元;上市申請與興櫃資料時點則為新台幣9億元,差異來自上市承銷與後續股本變動。2025年4月19日主要股東名單顯示,廣明光電持有70,457,000股、持股78.29%,台灣歐姆龍持有10,000,000股、持股11.11%,達明員工持股信託專戶持股7.50%,廣明員工福儲信託專戶持股1.29%;上市後董監持股資料顯示廣明光電持股約69,757,000股、台灣歐姆龍約9,900,000股。員工規模公開資料不完全一致:2024年媒體報導約435人,2025年上半年法人摘要約450人,其中研發人員約43%、工程人員約13%;112年度年報片段則顯示合併員工約357至360人,故員工數以約400至450人區間看待較保守。
達明主要從事協作型工業用機器人之研究、開發、生產、製造與銷售,核心產品為內建視覺與AI能力的TM AI Cobot與TM AI Cobot S系列,包括TM5、TM7S、TM12、TM14、TM16、TM20、TM25S、TM30S等不同負載與臂長產品,另提供TMflow軟體、AI視覺、TM 3DVision、力量感知、TM Image Manager、TM AI+訓練伺服器、AOI Edge、配件與系統整合服務。公司商業模式包含標準協作手臂銷售、自動化整合方案、軟體與零配件銷售、經銷商與系統整合商通路,以及針對大型客戶的專案型導入。112年度產品營收結構:機器人手臂銷售約11.23億元、占89.16%;自動化整合方案及其他約1.37億元、占10.84%。113年度公開說明書摘要顯示外銷占85.03%、內銷占14.97%,反映達明高度仰賴海外市場與全球通路。2025年全年合併營收18.22億元、年增約23%,毛利率約50.9%至51%,稅後淨利約1.36億元,EPS約1.46元。主要應用領域包括半導體、電子與光電、汽車與EV、物流倉儲、食品飲料、金屬與精密加工、塑膠射出、家具、醫療與教育訓練。公司差異化在於協作手臂內建相機與AI視覺,將手臂控制、視覺定位、讀碼/OCR、尺寸量測、瑕疵檢測、AI訓練與推論整合至單一平台,降低外接視覺模組與治具成本。已揭露的下游案例包括經寶精密jpp-KY導入近50台TM AI Cobot用於航太與伺服器機殼少量多樣製程,以及SMC日本草加工廠2022至2025年累計導入約70台達明機器人。
2025至2028年成長動能主要來自四個方向。第一,全球製造業缺工、少量多樣生產、品質檢測與柔性自動化需求提升,協作型機器人滲透率仍有成長空間,達明以內建視覺與AI Cobot切入半導體、電子、汽車、物流、食品、能源與傳產場域。第二,產品組合由單純手臂硬體升級為Total Solution,包括AI、3D視覺、Palletizing Operator、Welding、TM Image Manager、TM25S、TM30S與AMR整合方案,有助於提高客單價與方案黏著度。第三,海外通路與策略客戶:公司公開資料稱已建置約100至近200家經銷商及系統整合商,合作夥伴遍及歐亞美澳,並與OMRON有聯合品牌與策略合作關係;若能提高直供大型客戶與方案型專案比重,營收可望較傳統經銷出貨更具可見度。第四,實體AI與人形/輪式人形機器人布局:2026年GTC資訊顯示達明發表TM Xplore I,結合人形上半身與輪式底座,搭載NVIDIA Jetson Thor,導入Isaac Sim、FoundationStereo與VLA多模態模型,目標場景為半導體製程、電子組裝與汽車製造等高價值場域。中長期若能將協作手臂、AMR、AI視覺、數位分身與人形平台整合為可複製方案,將打開2027至2028年新的成長曲線。主要風險包括:全球製造業資本支出循環、關稅與匯率波動、協作機器人價格競爭、Universal Robots、FANUC、ABB、KUKA、中國協作機器人品牌與台廠自動化業者競爭;AI與人形機器人仍處技術驗證至早期商業化階段,量產時程、成本、可靠度與實際訂單仍具不確定性;公司外銷比重高,若歐美或中國需求轉弱、通路庫存調整或地緣政治限制升高,營收波動可能放大。
This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.
This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.